中国经济网编者按：据经济参考报今日报道《蔓迪国际冲刺港交所 三年半分红超14亿元》，日前，在 三生制药（01530.HK）宣布将附属公司蔓迪国际分拆并独立上市后，蔓迪国际向港交所递交招股书， 华泰国际担任独家保荐人。此次港股IPO，蔓迪国际计划将募集资金用于提高研发能力、策略性业务合 作、数字化运营迭代以及品牌建设等。 值得注意的是，尽管蔓迪国际有较强的造血能力且营收规模仍在增长，但公司上市前夕大额分红引发投 资者关注。2022年至2024年，公司分别向股东宣派股息2.5亿元、4亿元和0元。今年上半年，公司宣派 了7.7亿元股息，超出上述3年之和。受此影响，公司流动资产净额由2024年的5.95亿元断崖式降至今年 上半年的40万元，公司解释称："由于股息宣派，导致应付股息增加6.7亿元。" 据新京报贝壳财经报道《蔓迪国际冲刺港交所：靠"头顶生意"半年收入超7亿，净利率连降》，当获客 成本上升，市场竞争加剧，蔓迪国际的盈利压力也在加大。自2023年攀至高点后，该公司整体净利率有 了下滑苗头，2022年至2024年分别为20.5%、27.8%和26.8%，今年上半年降至23.4%。 经济参考报：蔓迪国际三年半分红 ...

Core Viewpoint - The article highlights the growing market for men's grooming products, particularly focusing on the success of Minoxidil-based products from Mandi International, which is preparing for an IPO with a post-investment valuation of HKD 5.8 billion [1][2]. Company Overview - Mandi International, established in 1997, is a leading consumer pharmaceutical company in China, focusing on skin health and weight management solutions, particularly in the hair health sector [2][5]. - The company was spun off from Shenshan Pharmaceutical, which was founded in 1993 and became the first Chinese biopharmaceutical company listed on NASDAQ in 2007 [3][4]. Product Portfolio - Mandi International's product range includes the first-generation 5% Minoxidil solution, the second-generation 5% Minoxidil foam, and anti-hair loss shampoos [5][6]. - The flagship product, Mandi 5% Minoxidil foam, is the only approved domestic Minoxidil foam in China and has maintained a leading market position for ten consecutive years [6]. Market Performance - Mandi International's revenue for the years 2022 to 2025 shows a compound annual growth rate (CAGR) of 21.7%, with revenues of CNY 9.82 billion, CNY 12.28 billion, CNY 14.55 billion, and CNY 7.43 billion for the respective years [7]. - The net profit for the same period was CNY 2.02 billion, CNY 3.41 billion, CNY 3.90 billion, and CNY 1.74 billion, with net profit margins ranging from 20.5% to 27.8% [7]. Market Trends - The hair health management market in China is projected to grow from CNY 19.8 billion in 2018 to CNY 52.7 billion by 2024, with an expected CAGR of 11.3% from 2024 to 2035 [6]. - Approximately 339 million people in China suffer from hair loss, with over 60% of them being under 35 years old, indicating a significant market opportunity among the younger demographic [6]. Future Prospects - Mandi International is expanding its pipeline in skin health and weight management, with ongoing clinical trials for innovative products like Winlevi and Semaglutide [8].

Group 1: Strategy Research - The scale of insurance funds, wealth management, and pension funds in China exceeds 70 trillion, showing continuous growth with an asset allocation characterized by "fixed income as the base, equity gradually increasing" [2][4] - Insurance and social security funds heavily invest in A-shares, focusing on financial sectors while gradually increasing allocations in technology and growth areas [2][5] Group 2: Biopharmaceutical Research - The second batch of price negotiations under the US IRA has been announced, with the highest price reduction reaching 85%, effective from January 2027 [2][7] - The overall impact of the negotiations is limited as the negotiated products are close to patent cliffs [7][9] Group 3: Investment Characteristics - The asset scale of insurance funds, pension funds, and wealth management has surpassed 70 trillion, with insurance and wealth management each exceeding 30 trillion, accounting for over 80% of the total [5] - Fixed income remains the mainstay of asset allocation, with insurance funds favoring bonds and social security funds leaning towards equity investments [5][6] Group 4: A-Share Heavyweights - The core of A-share heavyweights is in the financial sector, but there is an increasing focus on growth attributes, particularly in technology and advanced manufacturing sectors [6][7] Group 5: Company Quarterly Reports - For Yaxiang Integration, the net profit attributable to shareholders increased by 40% in Q3 2025, with a gross margin improvement of 9 percentage points [16][17] - For Jin Yu Medical, operational efficiency has steadily improved, with significant cash flow enhancement despite a decline in revenue [24][25] Group 6: Industry Trends - The biopharmaceutical industry is facing challenges due to the impending patent cliffs, which may limit the impact of IRA negotiations on product sales [9][15] - The automotive industry, particularly GAC Group, is accelerating its electrification transformation and collaborating with Huawei to explore new growth avenues [28][29]

Group 1 - Pfizer has accelerated the development of SSGJ-707 (PF-4404) with plans to initiate at least 7 clinical trials, including two global Phase III trials starting in December targeting 1L sq-/nsq-NSCLC and metastatic colorectal cancer [1] - The company aims to expand SSGJ-707 into over 10 new indications and more than 10 new combination therapies by the end of 2026, including evaluating its use with Pfizer's extensive ADC product portfolio [1] - Pfizer has identified over 500 clinical centers across more than 25 countries for the development of PF-4404 and has completed domestic production in the U.S. to ensure efficient development and compliance with global registration requirements [1] Group 2 - The company plans to spin off its consumer pharmaceutical business, Mandi International, for a listing on the Hong Kong Stock Exchange, which will allow it to focus on prescription and innovative drugs [2] - The spin-off is expected to generate short-term investment returns and support the commercialization of new products after the separation [2] - The target price for the stock has been raised to 39.5 HKD due to strong clinical data and partner support, reflecting increased confidence in the global development of SSGJ-707 [2]

Core Insights - The focus in the PD-(L)1/VEGF bispecific antibody market has shifted from business development amounts to development efficiency and indication differentiation [1] - The competition is intensifying as multiple PD-(L)1/VEGF bispecific antibodies are entering Phase III clinical trials, emphasizing the importance of research speed and strategic indication planning [1] Domestic Indication Layout - The PD-(L)1/VEGF bispecific antibody market in China is characterized by rapid development and strategic positioning, with 康方生物/Summit’s Ivonescimab leading the way [2] - Ivonescimab has received approval for two indications in China, with projected sales of approximately 9 billion CNY in 2024 and 7.2 billion CNY in the first half of 2025, and a forecasted total sales exceeding 15 billion CNY in 2025 [2][3] Clinical Development and Market Potential - The first indication for Ivonescimab was approved in May 2024 for treating advanced non-squamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR-TKI therapy [3] - The second indication was approved in April 2025 for first-line treatment of PD-L1 positive (TPS≥1%) EGFR mutation negative and ALK negative advanced NSCLC [3] - The third indication for Ivonescimab is under review for first-line treatment of advanced squamous NSCLC [3] - The potential of the advanced lung cancer market is significant, with non-small cell lung cancer accounting for approximately 85% of all lung cancer cases [3] Competitive Landscape - The competitive landscape includes other key players such as BioNTech/BMS with PM8002 and Pfizer with SSGJ-707, both of which are also in late-stage clinical trials [5][6] - PM8002 is focusing on triple-negative breast cancer (TNBC) and small cell lung cancer (SCLC), while SSGJ-707 has initiated a head-to-head comparison with Keytruda for treating PD-L1 positive NSCLC [6][8] Global Market Dynamics - The global PD-(L)1/VEGF bispecific antibody market is dominated by three main players: 康方生物/Summit, BioNTech/BMS, and Pfizer, all of which are conducting Phase III clinical trials [8] - The strategies of these companies vary, with 康方生物 focusing on building a strong clinical barrier in the lung cancer market, BioNTech/BMS creating differentiation in TNBC and SCLC, and Pfizer leveraging its ADC advantages in colorectal cancer [18]

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing unprecedented growth, with significant revenue increases and profitability improvements, marking a transformative decade since the reform of drug review and approval systems in 2015 [1][6]. Group 1: Financial Performance - In the first three quarters of 2025, the innovative drug sector's listed companies achieved a revenue of 48.83 billion yuan, a 22% increase year-on-year, while the net profit attributable to shareholders was -460 million yuan, improving by 71% [1]. - In Q3 2025 alone, the sector generated a revenue of 19.2 billion yuan, reflecting a 51% increase, and a net profit of 1.1 billion yuan, marking a 147% improvement [1]. Group 2: Key Company Highlights - BeiGene reported a Q3 2025 revenue of 10.077 billion yuan, a 41.1% year-on-year increase, and a net profit of 689 million yuan, turning profitable [2]. - For the first three quarters of 2025, BeiGene's revenue reached 27.595 billion yuan, up 44.2% year-on-year, with a net profit of 1.139 billion yuan, also indicating a turnaround [2]. Group 3: Business Development (BD) Trends - The innovative drug sector's profitability turnaround is largely attributed to rapid commercialization of innovative products, revenue from licensing fees, and milestone payments [8]. - Business Development (BD) has become a crucial revenue source for innovative drug companies, with a significant increase in licensing agreements, which accounted for 91% of total BD transactions in 2024, up from 45% in 2021 [10]. Group 4: Market Dynamics - The surge in BD activities is driven by the impending patent cliffs faced by multinational corporations (MNCs), which are seeking to replenish their pipelines as many blockbuster drugs are nearing patent expiration [19]. - In the first three quarters of 2025, MNCs accounted for 20% of global transactions and 39% of total transaction value, indicating a strong interest in Chinese innovative drugs [16]. Group 5: Innovation and Development Speed - China has surpassed the US in the number of original innovative drugs entering clinical trials, with 4,382 new drugs compared to the US's 4,009 from 2015 to 2024 [23]. - The speed of drug development in China is 2-3 times faster than international counterparts, with costs being only 1/3 to 1/2 of global best practices [31]. Group 6: Policy Support - The Chinese government has implemented supportive policies for innovative drugs, including a dual-track insurance system to facilitate access to high-value drugs and optimized procurement processes to ensure quality and clinical needs [39][40]. - The ongoing reforms and strategic planning by the government are expected to bolster the innovative drug sector, providing a stable environment for growth and development [41].

Group 1 - The Hang Seng Biotechnology Index futures will be listed for trading on November 28, reflecting the overall performance of the biotechnology sector in the Hong Kong stock market, covering notable companies such as Innovent Biologics, BeiGene, WuXi Biologics, and others, and is expected to benefit from the overseas expansion of innovative drugs and AI healthcare market trends [2][3] Group 2 - On November 28, a total of 11 companies will have their restricted shares unlocked, with a total of 109 million shares, amounting to a market value of 2.599 billion yuan at the latest closing price, with Shandong Water Gas and EVE Energy leading in terms of share unlock volume [4] - 16 companies have disclosed stock repurchase progress on November 28, with one company proposing a repurchase exceeding 40 million yuan, and another company, Guizhou Sanli, disclosing a repurchase plan of up to 1.432 million yuan [5]

Core Viewpoint - The report from CMB International raises the target price for Sihuan Pharmaceutical (01530) to HKD 39.5, maintaining a "Buy" rating and highlighting it as a key industry recommendation [1] Group 1: Clinical Data and Development - Strong clinical data, unwavering support from partners, and extensive R&D experience have increased confidence in the global development success of the 707 project [1] - The overseas development of the 707 project is progressing rapidly [1] Group 2: Business Spin-off - Sihuan Pharmaceutical plans to spin off its consumer pharmaceutical business, Mandi International, for a listing in Hong Kong, through a distribution of shares and a global offering of new shares [1] - After the spin-off, Sihuan Pharmaceutical will no longer hold any equity in Mandi International, which currently holds 87.16% [1] - The spin-off is expected to bring short-term investment returns and allow the company to focus on prescription and innovative drugs, with the raised funds supporting the commercialization of self-developed innovative products [1]

Group 1: Hong Kong Real Estate Industry - The recovery of the Hong Kong real estate market is expected to be gradual and will encompass different asset sub-sectors, with residential properties being prioritized by investors, followed by quality retail assets and core office spaces [1] - The industry rating has been upgraded from "in-line" to "outperform," with Sun Hung Kai Properties (16 HK) and Link REIT (823 HK) identified as preferred picks for residential and commercial properties, respectively [1] - Key drivers for market recovery include improved macroeconomic uncertainty (especially interest rate cuts), significant policy easing, and the return of fundamental demand drivers [1] Group 2: Residential Market Outlook - Residential rental levels are projected to increase by approximately 3-5% in 2025, with annual increases of about 3% expected in 2026 and 2027 [1] - Residential property prices are anticipated to rise by 3-5% in 2025, 5% in 2026, and 5% in 2027 [1] Group 3: Retail and Office Market Outlook - Core retail rental growth is expected to be moderate over the next 12 months, with community mall rents projected to grow by about 3-5% [2] - The office sector has seen vacancy rates peak over the past 18 months, with core CBD areas recording positive net absorption for eight consecutive quarters; rental rates are expected to stabilize in the second half of 2025, laying the groundwork for a rebound in 2026 [2] Group 4: Sanofi's SSGJ-707 Development - Sanofi's partner, Pfizer, is accelerating the overseas clinical development of SSGJ-707, with plans to initiate at least seven clinical trials soon, including two global Phase III trials targeting 1L sq-/nsq-NSCLC and metastatic colorectal cancer [3] - Pfizer aims to expand the drug's indications and combination therapies significantly by the end of 2026, with over 10 new indications and more than 10 new combination therapies planned [3] Group 5: Three-Spring Pharmaceutical's Strategic Moves - Three-Spring Pharmaceutical plans to spin off its consumer pharmaceutical business, Mandi International, for a separate listing on the Hong Kong Stock Exchange, allowing the company to focus on its core prescription and innovative drug business [4][6] - The target price for Three-Spring Pharmaceutical has been raised to HKD 39.50, maintaining a "buy" rating and industry focus [7] Group 6: Li Auto's Performance and Future Outlook - Li Auto reported a net loss of HKD 620 million in Q3 due to recall costs, with gross margins declining to 15.5%; however, strong orders for new electric models are noted [8] - The company is expected to face short-term supply chain bottlenecks but anticipates a recovery with the introduction of a dual-supplier model in November [8]

Core Viewpoint - The article highlights the growing market for men's grooming products, particularly focusing on the success of Minoxidil-based products from Mandi International, which is preparing for an IPO. The company has seen significant growth driven by the increasing demand from younger consumers, particularly those born in the 1990s [1][2][12]. Company Overview - Mandi International, established in 1997, is a leading consumer pharmaceutical company in China, focusing on skin health and weight management solutions, with a primary emphasis on hair health [6][13]. - The company was spun off from 3SBio, which was founded in 1993 and became the first Chinese biopharmaceutical company listed on NASDAQ in 2007 [7][8]. Financial Performance - Mandi International's revenue for the years 2022 to 2025 is projected to grow from 9.82 billion to 14.55 billion, with a compound annual growth rate (CAGR) of 21.7%. Net profit is expected to increase from 2.02 billion to 3.90 billion during the same period [14]. - Over 90% of the company's revenue comes from the Mandi series products, with the Minoxidil foam's revenue share rising from 10.6% in the first half of 2024 to 38.7% in the same period of 2025 [14]. Market Position - Mandi's flagship product, the Mandi 5% Minoxidil foam, is the only domestically approved Minoxidil foam in China and has maintained the top position in the hair loss treatment market for ten consecutive years, holding approximately 57% market share in the hair loss drug market and 71% in the Minoxidil category by 2024 [13]. - The hair health management market in China is expected to grow from 198 billion in 2018 to 527 billion by 2024, with a projected CAGR of 11.3% from 2024 to 2035 [13]. IPO and Valuation - Mandi International submitted its main board IPO application on November 20, with a post-investment valuation of 58 billion HKD following a recent financing round [3][9]. - The company is backed by significant shareholders, including 3SBio, which holds approximately 87.16% of the shares, and other investors like GLWecan and Alibaba Health [8][9]. Future Prospects - Mandi International is expanding its product pipeline beyond hair health, with ongoing clinical trials for innovative products in skin health and weight management, including a unique acne treatment and a long-acting GLP-1 receptor agonist for weight management [15].